Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer

Francesco Montagnani, Antonella Chiriatti, Sara Licitra, Camillo Aliberti, Giammaria Fiorentini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC). Capecitabine and irinotecan combinations (XELIRI) have been developed for the treatment of this disease but randomized comparisons with standard infusional 5-FU and irinotecan (FOLFIRI) showed conflicting results. Patients and Methods: We searched the literature for randomized controlled trials comparing XELIRI to FOLFIRI for the treatment of metastatic colorectal cancer. Odds ratios with 95% confidence intervals were used to analyze dichotomous variables. Hazard ratios for progression and death were combined with an inverse variance method based on logarithmic conversion. The fixed-effect model and Mantel-Haenszel method were used. Heterogeneity was investigated with the Q-test and I2. Sensitivity analyses were performed. Results: Only 3 studies were identified, involving a total of 450 patients. XELIRI was associated with significantly shorter progression-free survival (PFS) and increased grade 3/4 gastrointestinal toxicities such as nausea, vomiting, and diarrhea. Severe neutropenia, however, was significantly more frequent with FOLFIRI. No differences in responses and febrile neutropenia events were observed. Conclusion: Our analysis suggest that the 2 regimens are not equivalent. XELIRI remains an option for the first-line treatment of metastatic CRC but FOLFIRI should be preferred as it confers more benefits in terms of PFS and induces fewer GI toxicities.

Original languageEnglish
Pages (from-to)243-247
Number of pages5
JournalClinical Colorectal Cancer
Volume9
Issue number4
DOIs
Publication statusPublished - Oct 1 2010

Fingerprint

irinotecan
Fluorouracil
Colorectal Neoplasms
Safety
oxaliplatin
Disease-Free Survival
Febrile Neutropenia
Therapeutics
Neutropenia
Nausea
Vomiting
Diarrhea
Randomized Controlled Trials
Odds Ratio
Confidence Intervals
Capecitabine

Keywords

  • Bevacizumab
  • FOLFIRI
  • XELIRI

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. / Montagnani, Francesco; Chiriatti, Antonella; Licitra, Sara; Aliberti, Camillo; Fiorentini, Giammaria.

In: Clinical Colorectal Cancer, Vol. 9, No. 4, 01.10.2010, p. 243-247.

Research output: Contribution to journalArticle

Montagnani, Francesco ; Chiriatti, Antonella ; Licitra, Sara ; Aliberti, Camillo ; Fiorentini, Giammaria. / Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. In: Clinical Colorectal Cancer. 2010 ; Vol. 9, No. 4. pp. 243-247.
@article{f0f0bfd5bf874f4b95c2be22a5e8b49c,
title = "Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer",
abstract = "Background: Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC). Capecitabine and irinotecan combinations (XELIRI) have been developed for the treatment of this disease but randomized comparisons with standard infusional 5-FU and irinotecan (FOLFIRI) showed conflicting results. Patients and Methods: We searched the literature for randomized controlled trials comparing XELIRI to FOLFIRI for the treatment of metastatic colorectal cancer. Odds ratios with 95{\%} confidence intervals were used to analyze dichotomous variables. Hazard ratios for progression and death were combined with an inverse variance method based on logarithmic conversion. The fixed-effect model and Mantel-Haenszel method were used. Heterogeneity was investigated with the Q-test and I2. Sensitivity analyses were performed. Results: Only 3 studies were identified, involving a total of 450 patients. XELIRI was associated with significantly shorter progression-free survival (PFS) and increased grade 3/4 gastrointestinal toxicities such as nausea, vomiting, and diarrhea. Severe neutropenia, however, was significantly more frequent with FOLFIRI. No differences in responses and febrile neutropenia events were observed. Conclusion: Our analysis suggest that the 2 regimens are not equivalent. XELIRI remains an option for the first-line treatment of metastatic CRC but FOLFIRI should be preferred as it confers more benefits in terms of PFS and induces fewer GI toxicities.",
keywords = "Bevacizumab, FOLFIRI, XELIRI",
author = "Francesco Montagnani and Antonella Chiriatti and Sara Licitra and Camillo Aliberti and Giammaria Fiorentini",
year = "2010",
month = "10",
day = "1",
doi = "10.3816/CCC.2010.n.036",
language = "English",
volume = "9",
pages = "243--247",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer

AU - Montagnani, Francesco

AU - Chiriatti, Antonella

AU - Licitra, Sara

AU - Aliberti, Camillo

AU - Fiorentini, Giammaria

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC). Capecitabine and irinotecan combinations (XELIRI) have been developed for the treatment of this disease but randomized comparisons with standard infusional 5-FU and irinotecan (FOLFIRI) showed conflicting results. Patients and Methods: We searched the literature for randomized controlled trials comparing XELIRI to FOLFIRI for the treatment of metastatic colorectal cancer. Odds ratios with 95% confidence intervals were used to analyze dichotomous variables. Hazard ratios for progression and death were combined with an inverse variance method based on logarithmic conversion. The fixed-effect model and Mantel-Haenszel method were used. Heterogeneity was investigated with the Q-test and I2. Sensitivity analyses were performed. Results: Only 3 studies were identified, involving a total of 450 patients. XELIRI was associated with significantly shorter progression-free survival (PFS) and increased grade 3/4 gastrointestinal toxicities such as nausea, vomiting, and diarrhea. Severe neutropenia, however, was significantly more frequent with FOLFIRI. No differences in responses and febrile neutropenia events were observed. Conclusion: Our analysis suggest that the 2 regimens are not equivalent. XELIRI remains an option for the first-line treatment of metastatic CRC but FOLFIRI should be preferred as it confers more benefits in terms of PFS and induces fewer GI toxicities.

AB - Background: Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC). Capecitabine and irinotecan combinations (XELIRI) have been developed for the treatment of this disease but randomized comparisons with standard infusional 5-FU and irinotecan (FOLFIRI) showed conflicting results. Patients and Methods: We searched the literature for randomized controlled trials comparing XELIRI to FOLFIRI for the treatment of metastatic colorectal cancer. Odds ratios with 95% confidence intervals were used to analyze dichotomous variables. Hazard ratios for progression and death were combined with an inverse variance method based on logarithmic conversion. The fixed-effect model and Mantel-Haenszel method were used. Heterogeneity was investigated with the Q-test and I2. Sensitivity analyses were performed. Results: Only 3 studies were identified, involving a total of 450 patients. XELIRI was associated with significantly shorter progression-free survival (PFS) and increased grade 3/4 gastrointestinal toxicities such as nausea, vomiting, and diarrhea. Severe neutropenia, however, was significantly more frequent with FOLFIRI. No differences in responses and febrile neutropenia events were observed. Conclusion: Our analysis suggest that the 2 regimens are not equivalent. XELIRI remains an option for the first-line treatment of metastatic CRC but FOLFIRI should be preferred as it confers more benefits in terms of PFS and induces fewer GI toxicities.

KW - Bevacizumab

KW - FOLFIRI

KW - XELIRI

UR - http://www.scopus.com/inward/record.url?scp=77957811330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957811330&partnerID=8YFLogxK

U2 - 10.3816/CCC.2010.n.036

DO - 10.3816/CCC.2010.n.036

M3 - Article

VL - 9

SP - 243

EP - 247

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 4

ER -